ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2009
Killer B lymphocytes: the evidence and the potential.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 96 citations in OpenAlex.
- Exacerbated experimental arthritis in Wiskott-Aldrich syndrome protein deficiency: modulatory role of regulatory B cells.European journal of immunology · 2014Trial
- Metabolic and neuroimmune control of rheumatoid arthritis: therapeutic implications of FXR and α7-nAChR axes.Inflammopharmacology · 2026Review
- The Immunopathogenesis of uveitis.Frontiers in medicine · 2026Review
- Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study.ImmunoTargets and therapy · 2026Article
- B cells in tumor metastasis: friend or foe?International journal of biological sciences · 2023Review
- Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities.Nature reviews. Cancer · 2022Review
- Marginal Zone B-Cell Populations and Their Regulatory Potential in the Context of HIV and Other Chronic Inflammatory Conditions.International journal of molecular sciences · 2022Review
- The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis.Biomedicines · 2022Review
- The emerging role of regulatory cell-based therapy in autoimmune disease.Frontiers in immunology · 2022Review
- Monitoring of B Cell in Kidney Transplantation: Development of a Novel Clusters Analysis and Role of Transitional B Cells in Transplant Outcome.Diagnostics (Basel, Switzerland) · 2021Article
- Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.Frontiers in immunology · 2021Article
- A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.Frontiers in immunology · 2021Review
- Advances of Regulatory B Cells in Autoimmune Diseases.Frontiers in immunology · 2021Review
- B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis.Frontiers in immunology · 2021Review
- Characterization and Activation of Fas Ligand-Producing Mouse B Cells and Their Killer Exosomes.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Immunoglobulin profile and B-cell frequencies are altered with changes in the cellular microenvironment independent of the stimulation conditions.Immunity, inflammation and disease · 2020Article
- Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer.International journal of oncology · 2020Article
- The Plasma Interleukin (IL)-35 Level and Frequency of Circulating IL-35Scientific reports · 2019Article
- Article
- Increased killer B cells in chronic HCV infection may lead to autoimmunity and increased viral load.Clinical and experimental immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Immune regulation plays a critical role in controlling potentially dangerous inflammation and maintaining health. The Fas ligand/Fas receptor axis has been studied extensively as a mechanism of killing T cells and other cells during infections, autoimmunity, and cancer. FasL expression has been primarily attributed to activated T cells and NK cells. Evidence has emerged that B lymphocytes can express FasL and other death-inducing ligands, and can mediate cell death under many circumstances. Among B cell subsets, the expression of both Fas ligand and IL-10 is highest on the CD5(+) B cell population, suggesting that CD5(+) B cells may have a specialized regulatory function. The relevance of killer B cells to normal immune regulation, disease pathogenesis, and inflammation is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.